Acquired purpura fulminans

Summary

Acquired purpura fulminans (MONDO:0018854) is a disease. A subtype of purpura fulminans — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 25

Clinical features

Signs & symptoms

Clinical features (HPO)

25 HPO clinical features (Orphanet curated; top 25 by frequency):

HPO ID	Term	Frequency
HP:0000988	Skin rash	Frequent (30-79%)
HP:0001063	Acrocyanosis	Frequent (30-79%)
HP:0001873	Thrombocytopenia	Frequent (30-79%)
HP:0001977	Abnormal thrombosis	Frequent (30-79%)
HP:0002958	Immune dysregulation	Frequent (30-79%)
HP:0003645	Prolonged partial thromboplastin time	Frequent (30-79%)
HP:0004855	Reduced protein S activity	Frequent (30-79%)
HP:0005521	Disseminated intravascular coagulation	Frequent (30-79%)
HP:0005543	Reduced protein C activity	Frequent (30-79%)
HP:0008066	Abnormal blistering of the skin	Frequent (30-79%)
HP:0008151	Prolonged prothrombin time	Frequent (30-79%)
HP:0011227	Elevated circulating C-reactive protein concentration	Frequent (30-79%)
HP:0011900	Hypofibrinogenemia	Frequent (30-79%)
HP:0012733	Macule	Frequent (30-79%)
HP:0025022	Decreased erythrocyte sedimentation rate	Frequent (30-79%)
HP:0025475	Erythematous macule	Frequent (30-79%)
HP:0031273	Shock	Frequent (30-79%)
HP:0031365	Macular purpura	Frequent (30-79%)
HP:0100758	Gangrene	Frequent (30-79%)
HP:0001399	Hepatic failure	Occasional (5-29%)
HP:0002170	Intracranial hemorrhage	Occasional (5-29%)
HP:0002664	Neoplasm	Occasional (5-29%)
HP:0011029	Internal hemorrhage	Occasional (5-29%)
HP:0100806	Sepsis	Occasional (5-29%)
HP:0025452	Pyoderma gangrenosum	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	acquired purpura fulminans
Mondo ID	MONDO:0018854
Orphanet	49566
SNOMED CT	725157006
UMLS	C4510896
MedGen	1377273
GARD	0018838
MedDRA	10037556
Is cancer (heuristic)	no

Also known as: acquired PF · acquired purpura fulminans

Disease family

This is a subtype of purpura fulminans. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood coagulation disease › thrombophilia › disseminated intravascular coagulation › purpura fulminans › acquired purpura fulminans

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.